Your browser doesn't support javascript.
loading
Deprescribing proton pump inhibitors: evidence-based clinical practice guideline
Farrell, B; Pottie, K; Thompson, W; Boghossian, T; Pizzola, L; Rashid, F. J; Rojas-Fernandez, C; Walsh, K; Welch, V; Moayyedi, P.
Affiliation
  • Farrell, B; University of Ottawa. CA
  • Pottie, K; University of Ottawa. CA
  • Thompson, W; University of Ottawa. CA
  • Boghossian, T; Ottawa Hospital. CA
  • Pizzola, L; Bruyère Research Institute. CA
  • Rashid, F. J; Ottawa Hospital. CA
  • Rojas-Fernandez, C; University of Waterloo. CA
  • Walsh, K; Toronto Central Community Care Access Centre. CA
  • Welch, V; University of Ottawa. CA
  • Moayyedi, P; University in Hamilton. Hamilton. CA
Can. fam. physician ; 63(5)May 2017.
Article in English | BIGG - GRADE guidelines | ID: biblio-948157
Responsible library: BR1.1
ABSTRACT

OBJECTIVE:

To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes.

METHODS:

Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process included the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, with a detailed evidence review in in-person, telephone, and online meetings. Uniquely, the guideline development process included a systematic review of PPI deprescribing trials and examination of reviews of the harm of continued PPI use. Narrative syntheses of patient preferences and resource-implication literature informed recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and then to health care professional associations for review and revisions made at each stage. A decision-support algorithm was developed in conjunction with the guideline.

RECOMMENDATIONS:

This guideline recommends deprescribing PPIs (reducing dose, stopping, or using "on-demand" dosing) in adults who have completed a minimum of 4 weeks of PPI treatment for heartburn or mild to moderate gastroesophageal reflux disease or esophagitis, and whose symptoms are resolved. The recommendations do not apply to those who have or have had Barrett esophagus, severe esophagitis grade C or D, or documented history of bleeding gastrointestinal ulcers.

CONCLUSION:

This guideline provides practical recommendations for making decisions about when and how to reduce the dose of or stop PPIs. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients.
Subject(s)
Full text: Available Collection: Tematic databases Health context: Sustainable Health Agenda for the Americas / Neglected Diseases Health problem: Goal 7: Evidence and knowledge in health / Diarrhea Database: BIGG - GRADE guidelines Main subject: Proton Pump Inhibitors / Deprescriptions / Gastrointestinal Diseases Type of study: Practice guideline / Prognostic study Language: English Journal: Can. fam. physician Year: 2017 Document type: Article Institution/Affiliation country: Bruyère Research Institute/CA / Ottawa Hospital/CA / Toronto Central Community Care Access Centre/CA / University in Hamilton/CA / University of Ottawa/CA / University of Waterloo/CA
Full text: Available Collection: Tematic databases Health context: Sustainable Health Agenda for the Americas / Neglected Diseases Health problem: Goal 7: Evidence and knowledge in health / Diarrhea Database: BIGG - GRADE guidelines Main subject: Proton Pump Inhibitors / Deprescriptions / Gastrointestinal Diseases Type of study: Practice guideline / Prognostic study Language: English Journal: Can. fam. physician Year: 2017 Document type: Article Institution/Affiliation country: Bruyère Research Institute/CA / Ottawa Hospital/CA / Toronto Central Community Care Access Centre/CA / University in Hamilton/CA / University of Ottawa/CA / University of Waterloo/CA
...